A study to assess the safety and efficacy of MANP, a new blood pressure lowering mediation in African Americans with high blood pressure.

Overview

About this study

The purpose of this study is to evaluate the cardiovascular properties of MANP in African Americans (AA) with hypertension.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Hypertension, defined as a mean supine blood pressure greater than 140/90 mmHg and taking at least one (1) standard of care therapies (including a diuretic, angiotensin converting enzyme inhibitor or angiotensin receptor blocker and a calcium channel blocker).
  • MDRD estimated GFR > 30 mL/min to be calculated at the screening visit by available serum creatinine.
  • Male or female African Americans.
  • Between the ages of 20 and 70 years.
  • Have a body mass index (BMI) within the range of 18–40 kg/m ^2.
  • Be able to communicate effectively with the study personnel.
  • Be adequately informed of the nature and risks of the study and give written informed consent prior to receiving study medication

Exclusion Criteria:

  • Known hypersensitivity or allergy to MANP or other natriuretic peptides.
  • Women of child bearing age.
  • Having received any investigational drug or device within 30 days prior to entry into the study.
  • A history (within the last 2 years) of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction.
  • A history of difficulty with donating blood or donated blood or blood products within 45 days prior to enrollment.
  • Clinically significant new illness in the 1 month before screening in the opinion of the investigator.
  • History of severe allergies.
  • History of coronary artery. disease, cerebrovascular disease, or syncope.
  • History of epilepsy or other seizure disorder.
  • History of organ transplantation.
  • Malignancy within 5 years.
  • Clinically significant intrinsic renal disease, renal artery stenosis, or history of fibromuscular dysplasia of the renal arteries.
  • Consumption of a phosphodiesterase-5 inhibitor.

Eligibility last updated 9/14/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Paul McKie, M.D.

Closed for enrollment

Contact information:

Trevor Stromme CCRP

(507)293-2754

Stromme.Trevor@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20411290

Mayo Clinic Footer